{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Tiotropium%29", "query": { "intervention": "Placebo (for Tiotropium)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Tiotropium%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T19:56:07.699Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01085045", "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "PT003 MDI", "type": "DRUG" }, { "name": "PT005 MDI", "type": "DRUG" }, { "name": "Placebo MDI", "type": "DRUG" }, { "name": "Tiotropium bromide 18 μg (Spiriva Handihaler®)", "type": "DRUG" }, { "name": "Formoterol Fumarate 12 μg (Foradil® Aerolizer®)", "type": "DRUG" }, { "name": "PT001 MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 118, "start_date": "2010-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 4, "location_summary": "Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Medford", "state": "Oregon" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01085045" }, { "nct_id": "NCT05165485", "title": "Phase 4 COPD and Suboptimal Inspiratory Flow Rate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Revefenacin", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" }, { "name": "Revefenacin Placebo", "type": "DRUG" }, { "name": "Tiotropium Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 404, "start_date": "2022-01-07", "completion_date": "2023-11-20", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 76, "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05165485" }, { "nct_id": "NCT03478683", "title": "A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "budesonide/formoterol", "type": "DRUG" }, { "name": "albuterol/salbutamol", "type": "DRUG" }, { "name": "FF/UMEC/VI", "type": "DRUG" }, { "name": "Placebo to match budesonide/formoterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "Placebo to match FF/UMEC/VI", "type": "DRUG" }, { "name": "placebo to match tiotropium", "type": "DRUG" }, { "name": "ELLIPTA", "type": "DEVICE" }, { "name": "MDI", "type": "DEVICE" }, { "name": "HandiHaler", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 729, "start_date": "2018-06-25", "completion_date": "2019-03-14", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 40, "location_summary": "Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more", "locations": [ { "city": "Gold River", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeBary", "state": "Florida" }, { "city": "Edgewater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03478683" }, { "nct_id": "NCT02006732", "title": "Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "olodaterol", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 809, "start_date": "2013-11", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 20, "location_summary": "Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Duluth", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02006732" }, { "nct_id": "NCT01426009", "title": "Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "EP-101 via nebulizer (eFlow®) 25 ug", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 50 ug", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 100 ug", "type": "DRUG" }, { "name": "Placebo EP-101", "type": "DRUG" }, { "name": "Tiotropium bromide via (Spiriva® Handihaler®)", "type": "DRUG" }, { "name": "Ipratropium bromide Inhalation Solution via Handihaler® DPI", "type": "DRUG" }, { "name": "EP-101 via nebulizer (eFlow®) 200 ug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sunovion Respiratory Development Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 140, "start_date": "2011-08", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Los Angeles, California • DeLand, Florida + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Madisonville", "state": "Kentucky" }, { "city": "North Dartmouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01426009" }, { "nct_id": "NCT00857766", "title": "A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "ADVAIR DISKUS™ 250/50mcg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 249, "start_date": "2009-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00857766" }, { "nct_id": "NCT03137992", "title": "Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Test Product (tiotropium bromide inhalation powder)", "type": "DRUG" }, { "name": "Reference Product (Spiriva®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lupin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 377, "start_date": "2017-11-21", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 34, "location_summary": "Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03137992" }, { "nct_id": "NCT01533935", "title": "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "tiotropium + Olodaterol", "type": "DRUG" }, { "name": "Tiotropium", "type": "DRUG" }, { "name": "Olodaterol", "type": "DRUG" }, { "name": "Respimat", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 291, "start_date": "2012-02", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-09-15", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Austell", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533935" }, { "nct_id": "NCT00773786", "title": "Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "COPD" ], "interventions": [ { "name": "Arformoterol (Brovana)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trinity Health Of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "40 Years to 90 Years" }, "enrollment_count": 20, "start_date": "2008-10", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2019-08-06", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 1, "location_summary": "Hartford, Connecticut", "locations": [ { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00773786" }, { "nct_id": "NCT02796677", "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)", "type": "DRUG" }, { "name": "Aclidinium bromide 400 μg (AB 400 μg)", "type": "DRUG" }, { "name": "Formoterol fumarate 12 μg (FF 12 μg)", "type": "DRUG" }, { "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg", "type": "OTHER" }, { "name": "Tiotropium 18 μg (TIO 18 μg)", "type": "DRUG" }, { "name": "Placebo to TIO 18 μg", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "40 Years to 130 Years" }, "enrollment_count": 1595, "start_date": "2016-07-05", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-10-05T19:56:07.699Z", "location_count": 85, "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796677" } ] }